MaxCyte’s therapeutic pipeline addressing unmet medical needs

Our CARMA knowledge and experience, coupled with our strong and growing non-clinical and translational research program, forms the basis of our cell therapy R&D platform and underscores the potential for generating a pipeline of novel, differentiated, CARMA cell therapies for cancer as well as other diseases with serious unmet needs.

To date, supported by preclinical efficacy and also by external research conducted at leading academic labs, including Johns Hopkins University 1 , our lead CARMA program, MCY-M11, a mesothelin directed CAR-PBMC therapy, is being evaluated in a Phase I clinical trial for ovarian cancer and peritoneal mesothelioma [NCT03608618]. In addition, we are also advancing research and development of next-generation CARMA-based cell therapies — those potentially engineered with functionality uniquely amenable to the CARMA approach — directed to mesothelin and other novel,
undisclosed targets.